Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.

Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, Frank R, Pietschmann T.

Antiviral Res. 2011 Feb;89(2):136-48. doi: 10.1016/j.antiviral.2010.12.005. Epub 2010 Dec 15.

PMID:
21167208
2.

Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents.

Buckwold VE, Beer BE, Donis RO.

Antiviral Res. 2003 Sep;60(1):1-15. Review.

PMID:
14516916
3.

Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening.

Zhang Y, Weady P, Duggal R, Hao W.

Antimicrob Agents Chemother. 2008 Feb;52(2):666-74. Epub 2007 Nov 26.

4.

A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication.

Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M.

Anal Biochem. 2004 Nov 15;334(2):344-55.

PMID:
15494142
5.

Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.

Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM.

Antiviral Res. 2005 Aug;67(2):76-82.

PMID:
15927278
6.

Screening of small-molecule compounds as inhibitors of HCV entry.

Yang JP, Zhou D, Wong-Staal F.

Methods Mol Biol. 2009;510:295-304. doi: 10.1007/978-1-59745-394-3_22.

PMID:
19009270
7.

Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system.

Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, Schmidt EV.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9847-52. Epub 2001 Aug 7.

8.

The hepatitis C virus life cycle as a target for new antiviral therapies.

Pawlotsky JM, Chevaliez S, McHutchison JG.

Gastroenterology. 2007 May;132(5):1979-98. Review.

PMID:
17484890
9.

In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin.

El-Farrash MA, Aly HH, Watashi K, Hijikata M, Egawa H, Shimotohno K.

Microbiol Immunol. 2007;51(1):127-33.

10.

Evaluation systems for anti-HCV drugs.

Moriishi K, Matsuura Y.

Adv Drug Deliv Rev. 2007 Oct 10;59(12):1213-21. Epub 2007 Aug 9. Review.

PMID:
17720275
11.

Selective inhibitors of hepatitis C virus replication.

Neyts J.

Antiviral Res. 2006 Sep;71(2-3):363-71. Epub 2006 Jun 23. Review.

PMID:
16843538
12.

[Evaluation and application of natural products for viral infections].

Hayashi K, Hayashi T, Lee JB.

Yakugaku Zasshi. 2010 Feb;130(2):171-6. Review. Japanese.

13.

Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.

Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z.

J Virol. 2005 Mar;79(5):2788-96.

14.

A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells.

Lee JC, Chang CF, Chi YH, Hwang DR, Hsu JT.

J Virol Methods. 2004 Mar 1;116(1):27-33.

PMID:
14715304
15.

Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.

Chan K, Robinson M, Yang H, Cornew S, Delaney Iv WE.

Antiviral Res. 2013 Apr;98(1):85-92. doi: 10.1016/j.antiviral.2013.01.005. Epub 2013 Feb 1.

PMID:
23376631
16.

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.

Guedj J, Neumann AU.

J Theor Biol. 2010 Dec 7;267(3):330-40. doi: 10.1016/j.jtbi.2010.08.036. Epub 2010 Sep 8.

PMID:
20831874
17.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

18.

Cellular models for the screening and development of anti-hepatitis C virus agents.

Gondeau C, Pichard-Garcia L, Maurel P.

Pharmacol Ther. 2009 Oct;124(1):1-22. doi: 10.1016/j.pharmthera.2009.05.010. Epub 2009 Jun 23. Review.

PMID:
19555718
19.

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.

Mondal R, Koev G, Pilot-Matias T, He Y, Ng T, Kati W, Molla A.

Antiviral Res. 2009 Apr;82(1):82-8. doi: 10.1016/j.antiviral.2008.12.012. Epub 2009 Jan 25.

PMID:
19174175
20.

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K.

Hepatology. 2003 Nov;38(5):1282-8.

PMID:
14578868

Supplemental Content

Support Center